Aa
Encouraging clinical trial begins - no injections!
Here's another encouraging possibility in its first stages that would have NO INJECTIONS!
New hepatitis C drug trials begin
The first human clinical trials have started on a new drug developed to treat infections caused by the hepatitis C virus.
The medication, taken orally, was first prepared at the Welsh School of Pharmacy at Cardiff University in 2008.
Laboratory tests showed it killed 90% of the virus at very low concentration.
Trials in healthy volunteers to assess the drug's safety are being held before its effectiveness on patients is tested in trials next year.
Approximately 170m people around the world are affected by hepatitis C, which can lead to liver cancer and cirrhosis and can be fatal.
It is the leading cause of liver transplantation in western countries.
“ We believe that INX-189 offers the possibility of more potency against hepatitis, more rapid action in the liver, and fewer side effects than existing treatments ”
Professor Chris McGuigan, Welsh School of Pharmacy
The current treatment involves two drugs - ribavirin and interferon, which has to be given as an injection.
Side effects are often severe and lead to patients failing to complete the treatment.
However, researchers at the university believe the new drug, INX-189, is one of the most potent of its kind developed to date.
US pharmaceutical company Inhibitex, which owns the licence to INX-189 and has been working with the Cardiff team, is running the trials.
'Encouraging progress'
Professor Chris McGuigan, of the Welsh School of Pharmacy, who is the academic lead on the project, said the trials were in a "a very early stage".
"However, progress has been encouraging so far, going from the laboratory to human trials within 18 months.
"We believe that INX-189 offers the possibility of more potency against hepatitis, more rapid action in the liver, and fewer side effects than existing treatments."
Cardiff University and Inhibitex filed a patent on INX-189 earlier this year. It has been cleared for human clinical trials by the Food and Drug Administration in the US.
Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/uk_news/wales/south_east/8680183.stm
Published: 2010/05/13 12:40:28 GMT
© BBC MMX
http://news.bbc.co.uk/2/hi/uk_news/wales/south_east/8680183.stm
New hepatitis C drug trials begin
The first human clinical trials have started on a new drug developed to treat infections caused by the hepatitis C virus.
The medication, taken orally, was first prepared at the Welsh School of Pharmacy at Cardiff University in 2008.
Laboratory tests showed it killed 90% of the virus at very low concentration.
Trials in healthy volunteers to assess the drug's safety are being held before its effectiveness on patients is tested in trials next year.
Approximately 170m people around the world are affected by hepatitis C, which can lead to liver cancer and cirrhosis and can be fatal.
It is the leading cause of liver transplantation in western countries.
“ We believe that INX-189 offers the possibility of more potency against hepatitis, more rapid action in the liver, and fewer side effects than existing treatments ”
Professor Chris McGuigan, Welsh School of Pharmacy
The current treatment involves two drugs - ribavirin and interferon, which has to be given as an injection.
Side effects are often severe and lead to patients failing to complete the treatment.
However, researchers at the university believe the new drug, INX-189, is one of the most potent of its kind developed to date.
US pharmaceutical company Inhibitex, which owns the licence to INX-189 and has been working with the Cardiff team, is running the trials.
'Encouraging progress'
Professor Chris McGuigan, of the Welsh School of Pharmacy, who is the academic lead on the project, said the trials were in a "a very early stage".
"However, progress has been encouraging so far, going from the laboratory to human trials within 18 months.
"We believe that INX-189 offers the possibility of more potency against hepatitis, more rapid action in the liver, and fewer side effects than existing treatments."
Cardiff University and Inhibitex filed a patent on INX-189 earlier this year. It has been cleared for human clinical trials by the Food and Drug Administration in the US.
Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/uk_news/wales/south_east/8680183.stm
Published: 2010/05/13 12:40:28 GMT
© BBC MMX
http://news.bbc.co.uk/2/hi/uk_news/wales/south_east/8680183.stm
Been following this INX-189 for a bit. New to this site. Do have some info on it but seek more.
Yeah, themselves! Down with RIBA!!! Injections meant little in the face of that demon.
I meant to say Ribavirin - that is if this "no injection" ommits Interferon... It's usually the Riba that makes people ill and want to kill someone...
Mag
Mag
Looks like they filed a patent for the new drug and the FDA gave the go ahead to test it. Be anxious to see the results!
That sounds great. I hope the trials go well, and unexpected sides don't show up. That would be much easier on people who have to treat in the future.
Another "wait and see".....
Keep looking upward!!!!!!!!
Another "wait and see".....
Keep looking upward!!!!!!!!
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
